A new pathway to detect heart disease early.

EchoNext turns the world's most common cardiac test into a next generation biomarker for the AI era.

500K+
Patients tested to date
91%
Increase in new clinically significant diagnoses
#1
Most read cardiac AI paper of all time, Nature 2025
As seen in
Nature The New York Times NEJM AI Nature Medicine JACC JAMA European Heart Journal Circulation Reuters STAT CNN Becker's Hospital Review
EchoNext

A new cardiac biomarker to transform the way we detect cardiac disease.

EchoNext reads a standard 12-lead ECG, the world's most common cardiac test, and surfaces patients who are likely to have structural heart disease. No new hardware.

01

Collect Data

Takes in all standard 12-lead ECGs. Minimal data needs means fastest IT integrations in the field.

02

AI Inference

Runs instantaneously across entire enterprise with routing to individual physicians and system champions.

03

Transform Care

Centralized team coordination ensures high-risk patients get to diagnosis and treatment.

System scale without retraining your workforce

EchoNext is deployed so that an individual clinician can impact the entire health system on day one.

Actionable, not incidental

System integration means each new patient has a plan to get to diagnosis and treatment, all wired into the workflows cardiology teams already use.

Impact clearly measured

We help you establish a baseline on day one. Then show the clear impact and results of EchoNext to prove the difference it makes.

Detects forms of structural heart disease including

LV systolic dysfunction RV systolic dysfunction Aortic stenosis Aortic regurgitation Mitral regurgitation Tricuspid regurgitation Pulmonic regurgitation Severe left ventricular hypertrophy Pulmonary hypertension Pericardial effusion
Newsroom

Latest from Pathway.

All news →
Partner with us

Deploy Pathway at your health system.